J Assist Farmac Farmacoecon, v.9, 3.2, p.33-45, jul. 2024. doi:10.22563/2525-7323.2024.v9.n.3.p.33-45 33 Jornal de Assistência Farmacêutica e Farmacoeconomia v.9, n.3, p.33-45, jul. 2024. Artigo Original Chronic Obstructive Pulmonary Disease in Brazil: Cost of Illness Analysis Doença Pulmonar Obstrutiva Crônica no Brasil: Cost of illness analysis Suellen Mendes¹, Wallace Entringer Bottacin², Helena Hiemisch Lobo Borba³, Ana Carolina Melchiors 3 1 Mestre em Assistência Farmacêutica, Universidade Federal do Paraná (PP[1] GASFAR), Curitiba, Paraná, Brasil 2 Mestre em Ciências Farmacêuticas, Universidade Federal do Paraná (PP[1] GASFAR), Curitiba, Paraná, Brasil 3 Doutora em Ciências Farmacêuticas, Universidade Federal do Paraná (PP[1] GASFAR), Curitiba, Paraná, Brasil Autor correspondente: wallace.bottacin@gmail.com Como citar este artigo: Mendes S, Bottacin WE, Borba HHL, Melchiors C. Chronic Obstructive Pul- monary Disease in Brazil: Cost of Illness Analysis. JAFF [Internet]; 2024; 9(3): doi: 10.22563/2525-7323.2024.v9.n.3. p.32-44 Recebido em 28/11/2023 Aceito para publicação em 19/03/2024 ABSTRACT Objective: To measure the cost of Chronic Obstructive Pulmonary Disease (COPD) in Brazil to present an updated overview of the economic impact. Methods: A descriptive and retrospective analysis was carried out using macro and micro-costing techniques. It was based on information available in the Brazilian Ministry of Health’s databases, na- tional and international guidelines for the clinical management of COPD, and the opinion of specialists. The time horizon adopted included the period from January to December 2019 and considered the direct medical costs linked to the provision of health care. Results: The analysis revealed that the costs of hospital management of COPD totaled BRL107,867,664.40. In addition, it was evidenced that there is a substantial increase in the cost related to the management of the stable phase of the disease according to the severity of the condition, ranging from BRL 418.50 [2019] (USD 253.69 [price year 2024]) for Stage I to BRL 4,257.53 [2019] (USD 2,580.88 [price year 2024]) for Stage IV. Conclusion: This cost analysis and the estimated prevalence of COPD identified in Brazil demonstrate the importance of implementing effective strategies and public policies aiming to reduce risk factors associated with the disease. Keywords: Chronic Obstructive Pulmonary Disease (COPD); Cost of Illness; Unified Heal- th System; Brazil Funding: This work was self-funded. Disclosure statement. The authors report there are no competing interests to declare.